+1 (866) 450-4223 sales@dermtech.com

Enhanced early melanoma detection through the power of precision genomics.

Scar-free melanoma skin cancer detection is possible with the DermTech PLA – a breakthrough, genomic test that accurately assesses suspicious moles. Get peace of mind without giving a piece of you.

Early detection of melanoma skin cancer is critical to increase your chance of survival.

WHEN DIAGNOSED AT THE LOCAL STAGE

5-year relative survival rate

WHEN DIAGNOSED AT THE REGIONAL STAGE

5-year relative survival rate

WHEN DIAGNOSED AT THE DISTANT STAGE

5-year relative survival rate

The PLA provides enhanced early detection of melanoma to give you peace of mind.

What is the PLA?

DermTech PLA is a breakthrough, scar-free genomic test for the early detection of melanoma, giving you a clear answer about a suspicious mole. The PLA helps your dermatologist detect melanoma skin cancer in its earliest stages.

How does it work?

The PLA’s adhesive patch sticks to a mole like tape and is peeled off painlessly to collect skin cells. Skin cells that stick to the adhesive patch are analyzed in a lab where the cells are examined for two genes that can indicate the presence of melanoma. This gene expression analysis enables DermTech to accurately distinguish between melanoma and non-melanoma.

Is it right for me?

Melanoma is hard to visually identify and it is both under- and over-diagnosed. With the PLA, there is less than 1% chance of missing melanoma. Using the PLA results in fewer unnecessary biopsies, which means less pain and scarring. The PLA’s adhesive patch skin cell collection is pain-free, scalpel-free, and scar-free.

What to expect:

Your dermatologist will determine your treatment based on the results of the PLA. A mole with a negative result will be monitored and usually not biopsied, avoiding unnecessary surgery. A mole with a positive result will be biopsied per the current standard of care.

Get peace of mind without giving a piece of you.

Melanoma is the deadliest form of skin cancer in the U.S. There are about 190,000 cases of invasive and in situ melanoma cases diagnosed each year. 

An estimated 7,230 people will die of melanoma in 2019.

The PLA helps your dermatologist detect melanoma in its earliest stages when a high cure rate is possible.

25 negative surgical biopsies are performed to find one mole positive for melanoma.

Approximately 90% of surgical biopsies are performed on negative lesions. 1

Many early-stage melanomas are misinterpreted with the current diagnosis pathway.

The PLA reduces the probability of missing a melanoma to less than 1%. 2, 3

The PLA test for melanoma helps avoid unnecessary biopsies and scars.